原发皮肤淋巴组织增殖性疾病分类进展

doi:10.3760/cma.j.issn.0412-4030.2019.09.013

中华皮肤科杂志 ›› 2019, Vol. 52 ›› Issue (9): 647-651.doi: 10.3760/cma.j.issn.0412-4030.2019.09.013

原发皮肤淋巴组织增殖性疾病分类进展

陈浩¹ 孙建方¹ 周小鸽²

¹中国医学科学院北京协和医学院皮肤病医院病理科，南京 210042；²首都医科大学附属北京友谊医院病理科 100050

收稿日期:2019-03-11 修回日期:2019-06-25 出版日期:2019-09-15 发布日期:2019-08-30
通讯作者: 孙建方; 周小鸽 E-mail:fangmin5758@aliyun.com;zhouxiaoge59@hotmail.com
基金资助:
江苏省六大人才高峰项目（WSN-030）；中国医学科学院医学与健康科技创新工程项目（CIFMS-2017-12M-1-017）；北京协和医学院协和青年基金（3332017168）

Classification for primary cutaneous lymphoproliferative disorders: an update

Chen Hao¹, Sun Jianfang¹, Zhou Xiaoge²#br#

¹Department of Pathology, Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China; ²Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2019-03-11 Revised:2019-06-25 Online:2019-09-15 Published:2019-08-30
Contact: Sun Jianfang; Zhou Xiaoge E-mail:fangmin5758@aliyun.com;zhouxiaoge59@hotmail.com
Supported by:
Six Talent Peaks Project of Jiangsu Province （WSN-030）; CAMS Innovation Fund for Medical Sciences （CIFMS-2017-I2M-1-017）; PUMC Youth Fund （3332017168）

摘要/Abstract

摘要： 【摘要】原发皮肤淋巴组织增殖性疾病是一组主要累及皮肤、但与淋巴结病变不同的异质性病变。虽相对少见，仍是淋巴造血系统病变中的重要组成部分。在2017年版WHO淋巴造血组织疾病分类及2018年的皮肤淋巴瘤WHO-欧洲癌症研究和治疗组织（EORTC）分类中，大多数疾病分类较前没有变化，但对一些疾病，如EB病毒相关的淋巴组织增殖性疾病和原发皮肤CD4+小/中T细胞淋巴增殖性疾病的认知有新的改变，增加了新的病种。本文基于2017年版WHO分类和2018年WHO?EORTC分类介绍皮肤淋巴组织增殖性疾病分类的新进展。

关键词: 淋巴组织增殖性疾病；淋巴瘤, T细胞, 皮肤；淋巴瘤, 结外NK-T细胞；淋巴瘤, B细胞

Abstract: Primary cutaneous lymphoproliferative disorders are a group of heterogeneous diseases that mainly involve in skin and are completely different from lymph node lymphomas. Although rare, it is still an important part of lymphoid and hematopoietic tumors, and has many classification schemes. In the 2017 classification scheme of the World Health Organization and the 2018 updated version of WHO - EROTC classification, most entities did not change, but for some diseases, such as Epstein-Barr virus associated lymphoid tissue proliferative diseases and primary cutaneous CD4 positive small/medium T-cell lymphoma have modified, while new diseases have added. In this paper, the clinic and histologic features of these new and modified entities of primary cutaneous lymphomas are reviewed based on the the 2017 WHO and the 2018 WHO-EROTC classifications.

Key words: Lymphoproliferative disorders, Lymphoma, T-cell, cutaneous, Lymphoma, extranodal NK-T-cell, Lymphoma, B-cell

陈浩孙建方周小鸽. 原发皮肤淋巴组织增殖性疾病分类进展[J]. 中华皮肤科杂志, 2019, 52(9): 647-651.doi:10.3760/cma.j.issn.0412-4030.2019.09.013

Chen Hao, Sun Jianfang, Zhou Xiaoge. Classification for primary cutaneous lymphoproliferative disorders: an update[J]. Chinese Journal of Dermatology, 2019, 52(9): 647-651.doi:10.3760/cma.j.issn.0412-4030.2019.09.013

参考文献 22

［1］	Willemze R, Jaffe ES, Burg G, et al. WHO⁃EORTC classification for cutaneous lymphomas［J］. Blood, 2005,105（10）:3768⁃3785. doi: 10.1182/blood⁃2004⁃09⁃3502.
［2］	Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues［M］. 4th ed. Lyon: IARC Press, 2008.
［3］	Elder DE, Massi D, Scolyer RA, et al. WHO classification of skin tumours［M］. 4th ed. Lyon: IARC Press, 2018.
［4］	Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO⁃EORTC classification for primary cutaneous lymphomas［J］. Blood, 2019,133（16）:1703⁃1714. doi: 10.1182/blood⁃2018⁃11⁃881268.
［5］	Wilcox RA. Cutaneous B⁃cell lymphomas: 2016 update on diagnosis, risk⁃stratification, and management［J］. Am J Hematol, 2016,91（10）:1052⁃1055. doi: 10.1002/ajh.24462.
［6］	van Santen S, Roach RE, van Doorn R, et al. Clinical staging and prognostic factors in folliculotropic mycosis fungoides［J］. JAMA Dermatol, 2016,152（9）:992⁃1000. doi: 10.1001/jamadermatol. 2016.1597.
［7］	Plaza JA, Feldman AL, Magro C. Cutaneous CD30⁃positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases［J］. J Cutan Pathol, 2013,40（2）:236⁃247. doi: 10.1111/cup.12047.
［8］	McQuitty E, Curry JL, Tetzlaff MT, et al. The differential diagnosis of CD8⁃positive （"type D"） lymphomatoid papulosis［J］. J Cutan Pathol, 2014,41（2）:88⁃100. doi: 10.1111/cup.12243.
［9］	Kempf W, Kazakov DV, Palmedo G, et al. Pityriasis lichenoides et varioliformis acuta with numerous CD30+ cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases［J］. Am J Surg Pathol, 2012,36（7）:1021⁃1029. doi: 10.1097/PAS.0b013e31824f4f66.
［10］	Marschalkó M, Gyöngyösi N, Noll J, et al. Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis［J］. J Cutan Pathol, 2016,43（11）:963⁃973. doi: 10. 1111/cup.12779.
［11］	Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis［J］. Am J Surg Pathol, 2013,37（8）:1173⁃1181. doi: 10.1097/PAS. 0b013e318282d01e.
［12］	Onaindia A, Montes⁃Moreno S, Rodríguez⁃Pinilla SM, et al. Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features［J］. Histopathology, 2015,66（6）:846⁃855. doi: 10.1111/his.12529.
［13］	Petrella T, Maubec E, Cornillet⁃Lefebvre P, et al. Indolent CD8⁃positive lymphoid proliferation of the ear: a distinct primary cutaneous T⁃cell lymphoma?［J］. Am J Surg Pathol, 2007,31（12）:1887⁃1892. doi: 10.1097/PAS.0b013e318068b527.
［14］	Kluk J, Kai A, Koch D, et al. Indolent CD8⁃positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient［J］. J Cutan Pathol, 2016,43（2）:125⁃136. doi: 10.1111/cup.12633.
［15］	Cetinözman F, Jansen PM, Willemze R. Expression of programmed death⁃1 in primary cutaneous CD4⁃positive small/medium⁃sized pleomorphic T⁃cell lymphoma, cutaneous pseudo⁃T⁃cell lymphoma, and other types of cutaneous T⁃cell lymphoma［J］. Am J Surg Pathol, 2012,36（1）:109⁃116. doi: 10.1097/PAS.0b013e318230df87.
［16］	Balagué O, Martínez A, Colomo L, et al. Epstein⁃Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T⁃cell lymphomas: a phenomenon with distinctive clinicopathologic features［J］. Am J Surg Pathol, 2007,31（9）:1310⁃1322. doi: 10.1097/PAS.0b013e3180339f18.
［17］	Smith MC, Cohen DN, Greig B, et al. The ambiguous boundary between EBV⁃related hemophagocytic lymphohistiocytosis and systemic EBV⁃driven T cell lymphoproliferative disorder［J］. Int J Clin Exp Pathol, 2014,7（9）:5738⁃5749.
［18］	Ferreri AJ, Govi S, Ponzoni M. Marginal zone lymphomas and infectious agents［J］. Semin Cancer Biol, 2013,23（6）:431⁃440. doi: 10.1016/j.semcancer.2013.09.004.
［19］	Schreuder MI, Hoefnagel JJ, Jansen PM, et al. FISH analysis of MALT lymphoma⁃specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma［J］. J Pathol, 2005,205（3）:302⁃310. doi: 10.1002/path.1711.
［20］	Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets［J］. Am J Surg Pathol, 2010,34（12）:1830⁃1841. doi: 10.1097/PAS. 0b013e3181f72835.
［21］	van Maldegem F, van Dijk R, Wormhoudt TA, et al. The majority of cutaneous marginal zone B⁃cell lymphomas expresses class⁃switched immunoglobulins and develops in a T⁃helper type 2 inflammatory environment［J］. Blood, 2008,112（8）:3355⁃3361. doi: 10.1182/blood⁃2008⁃01⁃132415.
［22］	Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer⁃⁃a study of 26 cases associated with various sources of immunosuppression［J］. Am J Surg Pathol, 2010,34（3）:405⁃417. doi: 10.1097/PAS.0b013e3181cf8622.

[1]	秦俊霞秦小卫赵鹏. T细胞免疫球蛋白和黏蛋白结构域蛋白3抑制银屑病患者CD14+单核细胞分泌白细胞介素12 [J]. 中华皮肤科杂志, 2019, 52(9): 598-603.
[2]	覃慧郑捷. 鞘氨醇1-磷酸盐受体拮抗剂（FTY720）抑制皮肤中分泌白细胞介素17的γδT细胞治疗银屑病的机制研究[J]. 中华皮肤科杂志, 2019, 52(6): 395-400.
[3]	杨骥杨雪杨洁李明. 黄芩苷对狼疮鼠肾炎的治疗作用和对滤泡辅助T细胞的调控作用[J]. 中华皮肤科杂志, 2019, 52(3): 167-171.
[4]	宋翠豪王睿陈双景郑力强赵梓纲杨京润李承新. 二甲双胍对HaCaT细胞增殖分化和炎症因子分泌的影响[J]. 中华皮肤科杂志, 2019, 52(1): 25-32.
[5]	甘璐陈浩孙建方. 组蛋白甲基转移酶EZH2参与淋巴瘤发病机制的研究进展[J]. 中华皮肤科杂志, 2019, 0(0): 20180696-20180696.
[6]	刘娜覃慧郑捷. 组织常驻记忆性T细胞与银屑病[J]. 中华皮肤科杂志, 2018, 51(8): 630-632.
[7]	陈玲境韩睿程浩. 原发肾上腺NK/T细胞淋巴瘤皮肤侵犯一例[J]. 中华皮肤科杂志, 2018, 51(7): 544-545.
[8]	杨赛琳许文林福全周妙妮许爱娥. 他克莫司对γ干扰素刺激HaCaT细胞分泌趋化因子CXCL9和CXCL10的影响及机制研究[J]. 中华皮肤科杂志, 2018, 51(5): 375-378.
[9]	邓蕙妍李华平陈荃李润祥梁碧华高爱莉周欣朱慧兰. 紫檀芪对中波紫外线照射的HaCaT细胞抗氧化物酶表达及活性的影响[J]. 中华皮肤科杂志, 2018, 51(4): 274-278.
[10]	刘颖迪柏冰雪任静马良娟. 外源性胆绿素对中波紫外线诱导的HaCaT细胞光损伤的保护作用[J]. 中华皮肤科杂志, 2018, 51(4): 279-282.
[11]	薛晨红张宏伟彭芬何聪芬王巧娥陈周张建中. 空气细颗粒物PM2.5对HaCaT细胞增殖、细胞周期及凋亡的影响[J]. 中华皮肤科杂志, 2018, 51(3): 204-208.
[12]	张洪长左立春孙海才律广富李娜林喆. 枸杞多糖对中波紫外线照射HaCaT细胞低氧诱导因子1α、血管内皮细胞生长因子表达的影响[J]. 中华皮肤科杂志, 2017, 50(9): 667-670.
[13]	彭丽倩张尔婷刘清江娜李华平梁碧华李润祥李振洁朱慧兰. 枸杞多糖粗提物对紫外线诱导HaCaT细胞清除活性氧的影响[J]. 中华皮肤科杂志, 2017, 50(8): 557-561.
[14]	姚秋楠魏志平刘彦群. 葫芦素I对HaCaT细胞体外增殖及对角蛋白17、STAT3、VEGF表达的影响[J]. 中华皮肤科杂志, 2017, 50(6): 431-435.
[15]	王岚琦鞠强. 玫瑰痤疮发生的免疫学研究进展[J]. 中华皮肤科杂志, 2017, 50(3): 219-221.

原发皮肤淋巴组织增殖性疾病分类进展

Classification for primary cutaneous lymphoproliferative disorders: an update

PDF

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

Metrics

本文评价

推荐阅读 10